Prostate Cancer

Saruparib plus an androgen receptor pathway inhibitor was safe and active in metastatic prostate cancer.

Scott T. Tagawa, MD, MS, FACP, FASCO, discusses the background of a phase 3 trial of lutetium Lu 177 vipivotide tetraxetan plus ARPI and ADT in mHSPC.

Neeraj Agarwal, MD, FASCO, and Neal Shore, MD, FACS, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in prostate cancer presented during the 2025 ESMO Congress.

A reduced docetaxel regimen helped lower rates of AEs when combined with daolutamide and ADT in mHSPC.

Lutetium Lu 177 vipivotide tetraxetan plus an ARPI and ADT improved rPFS in metastatic hormone-sensitive prostate cancer.

Enzalutamide plus leuprolide acetate led to a 40.3% lower risk of death vs leuprolide acetate alone in high-risk, biochemically recurrent prostate cancer.

Capivasertib plus abiraterone acetate, prednisone, and androgen deprivation therapy was active in PTEN-deficient de novo metastatic HSPC.

[The baseline patient population] represents what we see in the real world, with a median age of 73. [This] is older than what we see in [many] clinical trials.

Alicia Morgans, MD, MPH, discusses the role of radioligand therapies for mCRPC and the importance of shared decision-making in prostate cancer management.

Alicia Morgans, MD, MPH, discusses data from the PEACE-3 trial that support the use of radium-223 plus enzalutamide in patients with mCRPC.

64Cu-SAR-bisPSMA displayed a higher detection rate of PSMA-positive prostate cancer lesions vs 68Ga-PSMA-11 PET/CT in patients with low PSA levels.

The AMPLITUDE trial met its primary end point of rPFS with niraparib regimen vs placebo in metastatic castration-sensitive prostate cancer.

DeLLpro-300 data provide preliminary evidence for the safety and activity of tarlatamab in DLL3-positive neuroendocrine prostate cancer.

Fred Saad, MD, discusses the rationale behind the long-term safety analysis for radium-223 dichloride and enzalutamide in metastatic castration-resistant prostate cancer with bone-predominant disease.

A panel of experts discusses the effort to personalize treatment approaches in metastatic castration-sensitive prostate cancer.

The top 5 OncLive TV videos of the week cover insights in lung cancer, and prostate cancer, myelofibrosis.

David Olmos, MD, PhD, discusses the evaluation of homologous recombination repair alterations in metastatic hormone-sensitive prostate cancer.

Phillip Koo, MD, discusses findings from a survey of prostate cancer screening rates.

Paul Gellhaus, MD, discusses ongoing developments with focal therapy in prostate cancer and potential avenues for technological improvement.

The FDA approved Enoby and Xtrenbo, denosumab biosimilars referencing Prolia and Xgeva, respectively.

Paul Gellhaus, MD, spotlights key technological advancements and the need for consensus on PSA screening guidance during prostate cancer awareness month.

Vote in OncLive's polls to share which lung and genitournary cancer abstracts you're most anticipating at the 2025 ESMO Congress.

Two denosumab biosimilars received approval from the FDA for the purpose of increasing bone mass in individuals at high risk for fracture.

Alicia Morgans, MD, MPH, shares her typical work week, the importance of saying yes to career opportunities, and the value of trusted team communication.